Table 1.
Distributions of participants in the pilot study.
| Characteristic | Participants, n (%) | |
| Total eligible participants (N=92) |
|
|
|
|
Participants with AMDa | 31 (33.7) |
|
|
Participants with PDb | 61 (66.3) |
| Total eligible participants who agreed to receive the ICFc by email (N=92) | 54 (58.7) | |
|
|
Participants with AMD (n=31) | 23 (74.2) |
|
|
Participants with PD (n=61) | 31 (50.8) |
| Total eligible participants who returned the signed ICF (n=54) | 36 (66.7) | |
|
|
Participants with AMD (n=23) | 17 (73.9) |
|
|
Participants with PD (n=31) | 19 (61.3) |
| Total eligible participants who completed the questionnaires at T1 (n=36) | 32 (88.8) | |
|
|
Participants with AMD (n=17) | 16 (94.1) |
|
|
Participants with PD (n=19) | 19 (100.0) |
| Total eligible participants who completed the questionnaires at T2 (n=30) | 24 (80.0) | |
|
|
Participants with AMD in the experimental group (n=10) | 7 (70.0) |
|
|
Participants with PD in the experimental group (n=10) | 10 (100.0) |
|
|
Participants with AMD or PD in the control group (n=10) | 7 (70.0) |
aAMD: anxiety and mood disorders
bPD: psychotic disorders.
cICF: Information and Consent Form.